Key Highlights

  • FibroBiologics (NASDAQ:FBLG) reported a third quarter net loss of USD 4,048 thousand, down from USD 5,778 thousand a year earlier, as total operating expenses fell 19% to USD 4,071 thousand.
  • Cash and cash equivalents were USD 1.2 million at September 30, 2026, against an accumulated Deficit of USD 67.3 million, and the filing flags substantial doubt about going concern.
  • Nine month operating cash outflow was USD 10.4 million, down from USD 13.2 million, funded by USD 6.7 million of net financing proceeds from stock sales and loans.
  • Common shares outstanding stood at 8,989,475 on November 16, 2026, after a one-for-20 reverse split effective March 30, 2026.

Third Quarter Loss Narrows as Costs Come Down

FibroBiologics (NASDAQ:FBLG) filed its Quarterly Report on November 16, 2026 for the three months ended September 30, 2026. Net loss was USD 4,048 thousand against USD 5,778 thousand a year earlier. Research and Development expense fell to USD 2,075 thousand from USD 2,789 thousand, mainly on lower contract research and supplies costs, and general, administrative and other expense fell to USD 1,996 thousand from USD 2,249 thousand. A year earlier the loss also carried an USD 846 thousand charge from the change in Fair Value of convertible debt. The company has no revenue. Interest income also fell to USD 20 thousand from USD 73 thousand, and a USD 9 thousand gain was booked on the Equity purchase agreement Put Option liability.

A Cell Therapy Pipeline Still Early in Development

FibroBiologics is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases including wound healing, psoriasis, multiple sclerosis and degenerative disc disease. Its lead candidate CYWC628 for diabetic wounds is in a twelve-week Phase 1/2 trial in Australia, and it filed a Phase 1/2 application for CYPS317 in psoriasis on December 30, 2025, which it is updating after FDA feedback. Over nine months, net loss was USD 13,165 thousand versus USD 15,402 thousand, with research and development up slightly to USD 6,686 thousand on higher trial costs. General expense fell to USD 6,486 thousand, even as Nasdaq listing costs rose by about USD 0.2 million.

Thin Cash Balance Keeps the Funding Question Open

Cash and cash equivalents were USD 1.2 million at September 30, 2026, after a nine month net decrease of USD 3,726 thousand. Operations used USD 10.4 million while financing brought in USD 6.7 million, including a registered offering with net proceeds of USD 2.6 million, private placements of USD 3.2 million, USD 0.8 million under an equity purchase agreement and USD 0.4 million from an at-the-market program. The company states that these factors raise substantial doubt about its ability to continue as a Going Concern for one year and that it must raise more Capital before any product revenue, so further dilution is a risk.

Where Things Stand

The filing says cash is tight. FibroBiologics (NASDAQ:FBLG) held USD 1.2 million at September 30, 2026 while burning USD 10.4 million from operations over nine months, so it needs new capital, and the company itself acknowledges going concern doubt. Lower research spending and the absence of last year's convertible Debt charge narrowed the quarterly loss to USD 4,048 thousand, but cost cuts alone do not close the gap. The next markers are further equity raises, FDA feedback on CYPS317, progress in the Australian wound healing trial and the Nasdaq listing requirements the company lists among its risks. Management also says it will accelerate its early longevity and cancer programs only as funding allows.